To investigate the budgetary implications of GLP-1 agonist use among non-diabetic individuals covered by Medicare.
Analyzed Medicare Part D data
Evaluated GLP-1 prescriptions
Assessed weight management coverage implications
Increased usage of GLP-1s observed among non-diabetics
Substantial budgetary pressures identified for Medicare
Ongoing policy discussions regarding expanded coverage of GLP-1s
Abstract
This growth underscores the substantial budgetary implications for Medicare, particularly amid ongoing policy discussions around expanding coverage of GLP-1s for weight management.